Latest News and Press Releases

NEW YORK, Dec. 15, 2005 (PRIMEZONE) -- As pharmaceutical companies increasingly concentrate on core competencies of sales and marketing, more alternatives to self-sufficiency from R&D are being...

NEW YORK, Dec. 7, 2005 (PRIMEZONE) -- Bioaccelerate Holdings Inc. (OTCBB:BACL) today announced that its portfolio company, Enhance Biotech Inc. (Pink Sheets:EBOI), a Specialty Pharmaceutical company...

NEW YORK and LONDON, Nov. 3, 2005 (PRIMEZONE) -- Bioaccelerate Holdings Inc. (OTCBB:BACL) today announces that Sir Charles George has agreed to be appointed to the Board of Directors. Professor Sir...

NEW YORK, Nov. 1, 2005 (PRIMEZONE) -- Few diseases cause more misery than psoriasis, a condition that occurs when a person's immune system overreacts and begins to attack the skin. Psoriasis is a...

DUBLIN, Ireland, Oct. 31, 2005 (PRIMEZONE) -- Newport Pharmaceuticals Ltd (NPL), a privately owned company focusing on immunological disorders, commented today on its phase II clinical development...

NEW YORK, Oct. 14, 2005 (PRIMEZONE) -- Bioaccelerate Holdings Inc, (OTCBB:BACL) announces that it has appointed Ronald A. Martell to its Board of Directors. Ronald Martell currently serves as...

NEW YORK, Oct. 5, 2005 (PRIMEZONE) -- Bioaccelerate Holdings, Inc., (OTCBB:BACL) today announces that it has appointed Dr George Butler, to its board of directors. Dr. Butler will serve as a...

NEW YORK, Sept. 16, 2005 (PRIMEZONE) -- Bioaccelerate Holdings Inc. (OTCBB:BACL) today announced that it has appointed Mark Davison as the Head of its CNS division. Mark Davison has over sixteen...

NEW YORK, Aug. 22, 2005 (PRIMEZONE) -- Evolve Oncology, Inc. (Pink Sheets:EVON), a clinical stage drug development company founded by Bioaccelerate Holdings, Inc. (OTCBB:BACL), announced today the...

NEW YORK, Jan. 5, 2005 (PRIMEZONE) -- Bioaccelerate Holdings Inc. (OTCBB:BACL) today announced that Dr. Frank Armstrong BSc (Hons) FRCPE, FFPM has agreed to join Bioaccelerate as its Chief Operating...